Comparative Pharmacology
Head-to-head clinical analysis: CLOPRA YELLOW versus VONTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOPRA YELLOW versus VONTROL.
CLOPRA-"YELLOW" vs VONTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clopra (metoclopramide) is a dopamine D2 receptor antagonist and, at higher doses, a serotonin 5-HT4 receptor agonist, which enhances gastrointestinal motility and accelerates gastric emptying. It also has central antiemetic effects via D2 blockade in the chemoreceptor trigger zone.
VONTROL (trimethobenzamide) acts centrally to inhibit the chemoreceptor trigger zone (CTZ) in the medulla oblongata, thereby suppressing nausea and vomiting. Its exact mechanism is not fully understood but may involve antagonism of dopamine D2 receptors and serotonin 5-HT3 receptors.
Adult: 25-50 mg orally 3-4 times daily; maximum 200 mg/day. For severe pain: 50-100 mg intramuscularly every 4-6 hours; maximum 300 mg/day.
10 mg orally twice daily; maximum 20 mg/day.
None Documented
None Documented
8-12 hours in normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min)
12 hours; prolonged in renal impairment (up to 24 hours in ESRD)
Renal: 70% unchanged, Biliary/Fecal: 20% as metabolites, 10% other
Renal: 60% unchanged; fecal: 30% (biliary); hepatic metabolism: 10%
Category C
Category C
Antiemetic/Prokinetic Agent
Antiemetic